The monitoring of patients post dosing in the trial proceeds with the last patient check out scheduled for the finish of September. In October with final assessment of the security data that occurs in November 2014 Data base lock is expected. The basic safety review undertaken to date confirms that there were no individual withdrawals or reports of any critical adverse events related to dosing with ATL1103 and that ATL1103 provides been assessed as generally well tolerated.21 in the Journal of the American University of Cardiology, revealed. After evaluating the timing of the last sexual activity before the coronary attack, only 0.7 % of the participants reported sex within an hour before their heart attack. A lot more than 78 %, however, reported that their last sexual activity occurred more than a day before the coronary attack. ‘Predicated on our data, it appears very unlikely that sexual activity is another trigger of coronary attack,’ study author Dr. Dietrich Rothenbacher, chair of the Institute of Epidemiology and Medical Biometry at Ulm University in Ulm, Germany, said in a news launch from the American University of Cardiology.